Dr. Eric Biron, PhD, is a Regular Researcher at the CHU de Québec Research Center and Full Professor at the Faculty of Pharmacy of Laval University. Recognized for his contributions in peptide chemistry, combinatorial chemistry and antimicrobial peptides, Dr. Biron is particularly interested in the use of peptidomimetic macrocycles and heterocycles in medicinal chemistry. His research focuses on the discovery and development of novel therapeutic agents for the treatment of infectious diseases and cancers.
Discovery and development of new antibacterial agents
The alarming spread of antibiotic resistance has become a major problem in the treatment of bacterial infections. In this context, Dr. Biron is particularly interested in bacteriocins, a family of low molecular weight proteins produced by several bacteria, with strong antimicrobial activity. As they exhibit inhibitory activities against a large number of clinically important pathogenic bacteria, bacteriocins are increasingly considered as a promising substitute to antibiotics.
Based on their enormous potential in the pharmaceutical and medical areas, Dr. Biron’s laboratory is developing novel synthetic approaches to produce bacteriocins, and uses peptidomimetic strategies to optimize their pharmacological properties, improve their pharmacokinetic profile, and modify their spectrum of activity.
Development of new anti-cancer agents
Despite the progress made in various therapeutic approaches, the effectiveness of main anti-cancer therapies has reached a critical plateau in the treatment of several cancers. As a result, the demand for innovative and effective compounds with new modes of action is growing rapidly. In this context, Dr. Biron’s laboratory uses combinatorial chemistry to prepare libraries with high molecular diversity and perform target-based or phenotypic screenings to discover promising anti-cancer molecules.
In another approach, Dr. Biron is interested in the addiction of cancer cells to some multifunctional proteins that also play an important role in the resistance to treatment. In this case, Dr. Biron’s laboratory aims to develop functional inhibitors of these proteins through rational design, and peptidomimetic approaches.
2705, boulevard Laurier
T4-50
Québec, Québec
Canada G1V 4G2
Latest news
- Bergeron, CatherineMaster studentCHUL+1 418-525-4444, extension 42296catherine.bergeron.1@crchudequebec.ulaval.ca
2705, boulevard Laurier
T-4-50
Québec, QC
Canada G1V 4G2 - Bergeron, CatherineDoctoral studentCHUL+1 418-525-4444, extension 42296catherine.bergeron.1@crchudequebec.ulaval.ca
2705, boulevard Laurier
T-4-50
Québec, QC
Canada G1V 4G2 - Bérubé, ChristopherPostdoctoral fellowCHUL+1 418-525-4444, extension 42296christopher.berube@crchudequebec.ulaval.ca
2705 Boulevard Laurier
T4-50
Québec, QC
Canada G1V 4G2 - Deblois, Laurie-AnneMaster studentCHUL+1 418-525-4444, extension 42296laurie-anne.deblois@crchudequebec.ulaval.ca
2705, boulevard Laurier
T4-50
Québec, QC
Canada G1V 4G2 - Fliss, OmarDoctoral studentomar.fliss@crchudequebec.ulaval.ca
- Guay, Louis-DavidEmployeeCHUL+1 418-525-4444, extension 42296louis-david.guay.2@ulaval.calouis-david.guay@crchudequebec.ulaval.ca
2705 Boulevard Laurier
T-450
Québec, QC
Canada G1V 4G2 - Guay, Louis-DavidDoctoral studentCHUL+1 418-525-4444, extension 42296louis-david.guay.2@ulaval.calouis-david.guay@crchudequebec.ulaval.ca
2705 Boulevard Laurier
T-450
Québec, QC
Canada G1V 4G2 - Lapointe, VictorMaster studentCHUL+1 418-525-4444, extension 42296victor.lapointe@crchudequebec.ulaval.ca
2705, boulevard Laurier
T4-50
Québec, QC
Canada G1V 4G2 - Rahman, Md Ramim TanverDoctoral studentCHUL+1 418-525-4444, extension 42296md-ramim-tanver.rahman@crchudequebec.ulaval.ca
2705 Boulevard Laurier
T4-50
Québec, QC
Canada G1V 4G2
The gliotransmitter ACBP controls feeding and energy homeostasis via the melanocortin system
Journal ArticleJ Clin Invest, 129 (6), 2019.
Recent Progress in the Chemical Synthesis of Class II and S-Glycosylated Bacteriocins
Journal ArticleFront Microbiol, 9 , 2018.
Synthesis, antimicrobial activity and conformational analysis of the class IIa bacteriocin pediocin PA-1 and analogs thereof
Journal ArticleSci Rep, 8 (1), 2018.
Synthetic Strategies for Macrocyclic Peptides
Book ChapterMarsault E, Peterson ML (Ed.): Practical medicinal chemistry with macrocycles : design, synthesis, and case studies, pp. 207-241, Hoboken, NJ, Wiley, 2017, ISBN: 9781119092568.
Convenient two-step synthesis of highly functionalized benzo-fused 1,4-diazepin-3-ones and 1,5-diazocin-4-ones by sequential Ugi and intramolecular SNAr reactions
Journal ArticleTetrahedron, 44 , 2017.
Toward solid-phase peptide fragment ligation by a traceless-Ugi multicomponent reaction approach
Journal ArticleOrg Biomol Chem, 14 (47), 2016.
One-Pot Photochemical Ring-Opening/Cleavage Approach for the Synthesis and Decoding of Cyclic Peptide Libraries
Journal ArticleOrg Lett, 18 (5), 2016.
Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer
Journal ArticleJ Steroid Biochem Mol Biol, 161 , 2016.
Collagencin, an antibacterial peptide from fish collagen: Activity, structure and interaction dynamics with membrane
Journal ArticleBiochem Biophys Res Commun, 473 (2), 2016.
A dual photochemical ring-opening/cleavage approach for the synthesis and decoding of one-bead-one-compound cyclic peptide libraries
Book ChapterSrivastava V, Yudin A, Lebl M (Ed.): Peptides 2015 : Proceedings of the twenty-fourth American peptide symposium, June 20-25, 2015, Orlando, FL, U.S.A, pp. 122-124, San Diego, CA, American Peptide Society, 2015, ISBN: 9780983974154.
Active projects
- Dérivatisation de triterpènes naturels par réactions multicomposantes pour le développement de nouveaux composés bioactifs biosourcés, from 2023-08-15 to 2027-08-14
- Exploiter l'addiction des bactéries au fer: Conception de nouvelles molécules hybrides bactériocine-sidérophore et évaluation de leur potentiel comme alternative aux antibiotiques, from 2021-04-01 to 2024-03-31
- Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
- New approaches for the design and synthesis of heterocyclic and macrocyclic bioactive peptidomimetics, from 2020-04-01 to 2025-03-31
Recently finished projects
- Design et synthèse d'acides aminés biosourcés pour la préparation de nouveaux triterpènes fonctionnalisés et de peptides conjugés, from 2020-01-13 to 2022-03-12
- Développement de nouvelles molécules bioactives et d’acides aminés biosourcés par dérivatisation de triterpènes naturels, from 2022-05-01 to 2023-06-30
- La conception de nouveaux agents thérapeutiques et la résonance magnétique nucléaire, from 2022-01-01 to 2023-05-31
- Laboratoire de pointe en chimie peptidique et biomoléculaire pour la découverte et la conception de molécules bioactives, from 2022-04-01 to 2023-09-28
- Valorisation de triterpènes naturels par dérivatisation pour le développement de nouvelles molécules bioactives biosourcées, from 2021-11-15 to 2022-11-14